Patient characteristics
Study populations included adults 18 to 82 years. Almost all studies
include both female and male participants. Several types of cancers were
accepted for participation, for instance, four studies included all
types of cancers. The most prevalent type was head and neck cancer in 11
studies(Planting et al., 1999, Madasu et al., 1995, Ishikawa et al.
2015, Duinkerken et al., 2021, Zuur et al., 2007, Rolland et al., 2019,
Yoo et al., 2014, Riga et al. 2013, Crabb et al., 2017, Fernandez et
al., 2021, Campbell et al. 2022). Other types were ovarian, bladder,
germ cell, gastric, lung, breast, sarcoma, thymus, mesothelioma,
esophagus, melanoma, and cancer of unknown origin. Most of the studies
recruited patients about to begin chemotherapy, with no prior history of
auditory surgery, affection, or disease, and good performance status.
Cisplatin dose ranged between 75 to 517 milligrams per square meter
(mg/m2), an average of 138 mg/m2. Study exclusion criteria varied, with
some studies excluding patients with metastasis in the central nervous
system, hepatic or renal insufficiency, hearing asymmetry, hearing aid
users, and concomitant neuropathy or radiotherapy. In regards to this
last condition, there was great heterogeneity between studies, 10
studies demanded or allowed concomitant radiotherapy (Planting et al.,
1999, Madasu et al., 1995, Ishikawa et al. 2015, Duinkerken et al.,
2021, Zuur et al., 2007, Rolland et al., 2019, Yoo et al., 2014,
Fernandez et al., 2021, Scasso et al. 2017, Campbell et al. 2022) while
13 considered radiotherapy as an exclusion criterion. For those studies
that reported follow-up time, the mean was 6,4 months.